---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-054818"
form_type: "8-K"
ticker: "INTS"
cik: "0001567264"
company_name: "INTENSITY THERAPEUTICS, INC."
filed_at: "2023-07-05T23:59:59+00:00"
generated_at: "2026-06-13T12:40:45.519488+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Intensity Therapeutics upsized IPO priced at $5.00/share; gross proceeds $19.5M

## Summary
- Sold 3,900,000 shares at $5.00/share for gross proceeds of $19.5M; net proceeds of $16.2M.
- Underwriters have 45-day option to purchase up to 585,000 additional shares at same price.
- Common stock began trading on Nasdaq Capital Market on June 30, 2023 under ticker 'INTS'.
- Net proceeds to fund clinical trials, operations, product development, and working capital.
- Amended and restated charter and bylaws effective upon closing of IPO.

## SEC filing metadata
- accession: 0001213900-23-054818
- form_type: 8-K
- ticker: INTS
- cik: 0001567264
- company_name: INTENSITY THERAPEUTICS, INC.
- filed_at: 2023-07-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567264/000121390023054818/0001213900-23-054818-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567264/000121390023054818/ea181296-8k_intensity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-054818
- JSON: https://secwatch.observer/filing/0001213900-23-054818.json
- Plain text: https://secwatch.observer/filing/0001213900-23-054818.txt

## Key facts
- Governance Changes
  INTENSITY THERAPEUTICS, INC.: Adopted amended and restated Bylaws effective upon closing of the Offering (effective 2023-07-05).
  - Change: bylaw amendment
  - Effective: 2023-07-05
  source text: In connection with the closing of the Offering, effective as of July 5, 2023, the Company adopted amended and restated bylaws (the “ Amended and Restated Bylaws ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1567264/000121390023054818/0001213900-23-054818-index.htm
- Governance Changes
  INTENSITY THERAPEUTICS, INC.: Filed Sixth Amended and Restated Certificate of Incorporation in connection with closing of the initial public offering (effective 2023-06-30).
  - Change: charter amendment
  - Effective: 2023-06-30
  source text: In connection with the closing of the Offering, on June 30, 2023, the Company filed its Sixth Amended and Restated Certificate of Incorporation (the “ Sixth Amended and Restated Charter ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1567264/000121390023054818/0001213900-23-054818-index.htm
- Material Agreements
  INTENSITY THERAPEUTICS, INC. entered into Underwriting Agreement with The Benchmark Company, LLC valued at Total gross proceeds of $19,500,000 from sale of 3,900,000 shares at $5.00 per share (effective 2023-06-29).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: The Benchmark Company, LLC
  - Value: Total gross proceeds of $19,500,000 from sale of 3,900,000 shares at $5.00 per share
  - Effective: 2023-06-29
  source text: On June 29, 2023, Intensity Therapeutics, Inc. (the “ Company ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with The Benchmark Company, LLC, as representative of the underwriters named on Schedule 1 thereto (the “Representative ”) relating to the Company’s firm commitment underwritten initial public offering (the “ Offering ”) of common stock, par value $0.0001 per share (the “ Common Stock ”), which was registered under the Securities Act of 1933, as amended (the “ Securities Act ”) by the Company’s registration statement on Form S-1, as amended (File No. 333-260565) (the “ Registration Statement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1567264/000121390023054818/0001213900-23-054818-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.